MedGenome’s Neo-epitope Prioritization Solution
MedGenome’s OncoPeptVAC neo-epitope prioritization and neo-antigen prediction solution is an NGS-based approach that analyzes exome data from a patient’s healthy tissue as well as RNA-seq data from tumor tissue.
OncoPeptVAC can be used to accelerate development of cancer vaccine candidates. Compatible with any tumor model, we combine a novel patent-pending TCR binding prediction with a conventional HLA binding prediction for better accuracy to identify, predict and prioritize vaccine candidates. Our analysis is consistent with the explanation that T-cell neo-epitopes are largely private and not shared between samples. Given the time-sensitive nature of neo-epitope prediction in cancer vaccine work, MedGenome offers a fast 2 week turnaround time.